These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23855951)

  • 1. Acute cardiovascular toxicity of low-dose intrathecal ziconotide.
    Heifets BD; Smith SM; Leong MS
    Pain Med; 2013 Nov; 14(11):1807-9. PubMed ID: 23855951
    [No Abstract]   [Full Text] [Related]  

  • 2. Using ziconotide for intrathecal infusions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L
    Nursing; 2008 Dec; 38(12):19. PubMed ID: 19033968
    [No Abstract]   [Full Text] [Related]  

  • 3. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide.
    Stanton-Hicks M; Kapural L
    J Pain Symptom Manage; 2006 Dec; 32(6):509-11. PubMed ID: 17157748
    [No Abstract]   [Full Text] [Related]  

  • 4. [Neuropsychiatric side effects of intrathecal ziconotide].
    Ayuga-Loro F; Brocalero-Camacho Á; Quintas-López MV; Cabrera-Feria JR
    Rev Neurol; 2011 Jan; 52(1):61-3. PubMed ID: 21246497
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recommendations for the management of chronic pain by intrathecal ziconotide].
    Tronnier V; Hofacker W; Ilias W; Kleinmann B; Koulousakis A; Kress HG; Likar R; Lux EA; Müller-Schwefe G; Schütze G; Uberall M
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():106-9. PubMed ID: 21595155
    [No Abstract]   [Full Text] [Related]  

  • 6. Ziconotide.
    Strigenz T
    J Pain Palliat Care Pharmacother; 2014 Mar; 28(1):73-4. PubMed ID: 24397285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged delirium with psychotic features from omega conotoxin toxicity.
    Obafemi A; Roth B
    Pain Med; 2013 Mar; 14(3):447-8. PubMed ID: 23383992
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.
    Rauck RL; Wallace MS; Leong MS; Minehart M; Webster LR; Charapata SG; Abraham JE; Buffington DE; Ellis D; Kartzinel R;
    J Pain Symptom Manage; 2006 May; 31(5):393-406. PubMed ID: 16716870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new approach to chronic pain.
    Barker E
    RN; 2005 May; 68(5):32ac1-32ac4; quiz 32ac5. PubMed ID: 15931928
    [No Abstract]   [Full Text] [Related]  

  • 12. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain.
    Wermeling DP; Berger JR
    Pharmacotherapy; 2006 Mar; 26(3):395-402. PubMed ID: 16503720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziconitide.
    Greenberg EN
    J Pain Palliat Care Pharmacother; 2011; 25(4):380-1. PubMed ID: 22126177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Italian registry on long-term intrathecal ziconotide treatment.
    Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
    Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziconotide-induced psychosis: a case report.
    Phan SV; Waldfogel JM
    Gen Hosp Psychiatry; 2015; 37(1):97.e11-2. PubMed ID: 25459190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.